Terms: = Lung cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Clinical Outcome
14 results:
1. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Robles AI; Faus-Dáder MJ; Calleja-Hernández MÁ
Mutat Res Rev Mutat Res; 2017; 771():32-58. PubMed ID: 28342452
[TBL] [Abstract] [Full Text] [Related]
2. Correlation of DNA Repair Gene Polymorphisms With clinical outcome in Patients With Locally Advanced Non-Small-Cell lung cancer Receiving Induction Chemotherapy Followed by Surgery.
Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
[TBL] [Abstract] [Full Text] [Related]
3. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell lung cancer Patients Treated With Platinum-Based Chemotherapy.
Kalikaki A; Voutsina A; Koutsopoulos A; Papadaki C; Sfakianaki M; Yachnakis E; Xyrafas A; Kotsakis A; Agelaki S; Souglakos J; Mavroudis D; Georgoulias V
Cancer Invest; 2015 Apr; 33(4):107-13. PubMed ID: 25647444
[TBL] [Abstract] [Full Text] [Related]
4. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract] [Full Text] [Related]
5. Polymorphisms in xpd gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.
Qin Q; Zhang C; Yang X; Zhu H; Yang B; Cai J; Cheng H; Ma J; Lu J; Zhan L; Liu J; Liu Z; Xu L; Sun X
PLoS One; 2013; 8(11):e79864. PubMed ID: 24260311
[TBL] [Abstract] [Full Text] [Related]
6. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Li XD; Han JC; Zhang YJ; Li HB; Wu XY
Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
[TBL] [Abstract] [Full Text] [Related]
7. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract] [Full Text] [Related]
8. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy.
Butkiewicz D; Drosik A; Suwiński R; Krześniak M; Rusin M; Kosarewicz A; Rachtan J; Matuszczyk I; Gawkowska-Suwińska M
Int J Cancer; 2012 Oct; 131(7):E1100-8. PubMed ID: 22511383
[TBL] [Abstract] [Full Text] [Related]
9. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.
Dong J; Hu Z; Shu Y; Pan S; Chen W; Wang Y; Hu L; Jiang Y; Dai J; Ma H; Jin G; Shen H
Mol Carcinog; 2012 Jul; 51(7):546-52. PubMed ID: 21739480
[TBL] [Abstract] [Full Text] [Related]
10. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
Metro G; Chiari R; Mare M; Giannarelli D; Tofanetti FR; Minotti V; Ferraldeschi M; Giuffrida D; Marcomigni L; Bennati C; Fischer MJ; Meacci M; Bellavita R; Pistola L; Ludovini V; Crinò L
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1405-12. PubMed ID: 21468755
[TBL] [Abstract] [Full Text] [Related]
11. An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer.
Butkiewicz D; Rusin M; Sikora B; Lach A; Chorąży M
Mol Biol Rep; 2011 Nov; 38(8):5231-41. PubMed ID: 21188533
[TBL] [Abstract] [Full Text] [Related]
12. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract] [Full Text] [Related]
13. Correlation of CDA, ERCC1, and xpd polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract] [Full Text] [Related]
14. Prospective assessment of xpd Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract] [Full Text] [Related]
